Pre-Conference Workshop Day

Tuesday, June 14 2022

Workshop A

Defining the Mechanistic Role of Myeloid Cell Populations in Tumorigenesis with Patient Samples & Identifying Novel Targets & Biomarkers for Clinical Development

• Decoding RNA signals, discussing the contributions of RNA sequencing to the field, and highlighting remaining limitations

• Investigating the phenotypic diversity and plasticity, and characterizing cell subsets

• Drawing functional conclusions to determine how different cell phenotypes impact therapeutic efficacy to inform combination approaches, using RNA analysis and proteomics

• Combining multiple datasets to create a comprehensive picture of the myeloid compartment, and draw functional conclusions from phenotypic data

• Analyzing the shared characteristics of the myeloid compartment across multiple tumor indications to identify which myeloid cells are present, and how their function varies, in human cancer

Workshop Leaders:

james Rubenstein

James Rubenstein
University of California San Francisco


Jasper Mullenders
Director Translational Research
Scenic Biotech

Workshop B

Modeling the Myeloid Compartment with In Vitro, Ex Vivo, and In Vivo Technologies to Enhance Translation and Mechanistic Understanding

• Highlighting the nuances of the tumor myeloid microenvironment vs. normal myeloid cells, and how to integrate this into model development

• Characterizing and translating broader and more diverse sub-cell types using models

• Managing lack of myeloid cell marker conservation across species and proposing industry solutions to enable gold standards for preclinical work, shared through a robust IND-ready preclinical package example

• Sharing work to recapitulate the tumor microenvironment and study cellular dynamics ex vivo

• Extracting and maintaining myeloid cells in models without modulating the myeloid phenotype

• Examining shared mechanisms that are apparent through in vitro and in vivo models

Workshop Leaders:


Jeffrey Pollard
Director of the MRC Center for
Reproductive Health
The University of Edinburgh

kareem azab

Kareem Azab
Associate Professor, Cancer
Biology Division, Department of
Radiation Oncology
Washington University St. Louis

Workshop C

Enhancing Target Identification & Validation to Take Aim at Therapeutically Significant Targets & Investigate their Functional Impact with RNASeq Bioinformatics Studies

• Considering the desirable characteristics of myeloid cell targets, and contrasting the benefits and challenges of targeting different cellular mechanisms such as cross-presentation, polarization, and pathway modulation

• Defining the cause of immune suppression by myeloid cells, identifying master regulators, and discussing which processes in a signaling pathway can be effectively targeted

• Selecting targets on myeloid subsets which are tumor-specific

• Discussing the challenges of demonstrating single agent effect on target validation, and tips to overcome these

• Sharing in vivo target validation workflows, and exploring translational and preclinical data to support target validation alongside clinical proof of myeloid targeting

• Decoding RNA signals, discussing the contributions of RNA sequencing to the field, and highlighting remaining limitations

Workshop Leaders:

kamal puri

Kamal Puri


Tatiana Novobrantseva
Co-Founder & CSO
Verseau Therapeutics

igor feldman

Igor Feldman
Co-Founder & CAO
Verseau Therapeutics